Filter your search
- $3,500.00 – $7,000.00The strategic interplay of of HIV/AIDS diagnostics and therapeutics is one of the most complex that the healthcare industry has ever seen. In order to cope with the challenges and opportunities of HIV/AIDS, companies must think on a global basis, and in addition to the basic pathology and complications of HIV/AIDS, there are societal and […]March 1, 2006$3,500.00 – $7,000.00There are hundreds of drugs in Phase III clinical trials, of which almost 200 of them may gain market approval from the FDA in the coming 5 years. Which drugs will make it and how these drugs impact existing pharmaceutical markets in terms of overall size and competitive share is one of the most difficult […]March 1, 2006$2,995.00 – $5,990.00The reinvigorated market for medical imaging systems employing x-rays has undoubtedly been propelled by the explosion of digital technology. But also, the expanded role of imaging modalities in a whole host of clinical applications from trauma to cancer to cardiology has increased the profile of radiography while enabling computer technologies expand the usefulness of traditional […]February 18, 2006$2,200.00 – $5,990.00Biopharmaceutical research and development is sure to dramatically increase the number of injectable drugs coming to market over the next few years. While advanced drug delivery techniques continue to hold promise for unique methods of administration, the traditional injection is still the dominant paradigm. However, the staggering costs and intransigent safety problems associated with sharps, […]February 18, 2006$3,000.00 – $6,000.00The private label over-the-counter (OTC) market has been gaining ground rapidly over the past five years. The private label sector has shed its image of being a ‘me-too’ version of national brands and worked toward offering quality and innovation at an economical price. With benefits for consumers, retailers, and manufacturers, private label healthcare should experience […]February 1, 2006$1,995.00 – $7,800.00This report provides the reader with a comprehensive analysis of the domestic and international markets involving pharmaceuticals to treat skin diseases and disorders. This edition of Worldwide Market for Prescription Dermatologic Drugs is the fifth time Kalorama Information has comprehensively studied the dermatology markets. As is the case with each new edition, Kalorama completely re-evaluated […]February 1, 2006$2,995.00 – $5,990.00The field of biotechnology instrumentation has been an expanding one ever since the emergence of the Human Genome Project 20 years ago. Although the filed certainly existed prior to that point in time, it was the Human Genome Project with its major access to key universities, national laboratories, and government funding sources that gave great […]January 1, 2006$995.00 – $5,990.00With the mapping of the human genome and the concomitant explosion of proteomics, a steady stream of biopharmaceuticals have been launched—recombinant therapeutic proteins, monoclonal antibody-based products used for therapeutic or in vivo diagnostic purposes, and nucleic acid-based products. As the rate of regulatory approval for biopharmaceuticals increases, the number of products reaching the market will […]January 1, 2006$3,000.00 – $6,000.00The U.S. Market for OTC anti-infective products surpassed the $2 billion mark last year. Although overall growth is sluggish, the market is a proven revenue source for a number of major brands, and there have been some nice surprises in the performance of some categories, such as first-aid related antiseptic and antibiotic products. This comprehensive […]January 1, 2006$3,500.00 – $7,000.00The U.S. long-term care industry experienced strong growth from 1999 through 2004 and this growth is expected to continue through the end of the decade. Indeed, the aging of the U.S. population will push unprecedented demand for all forms of long-term care, but ongoing cost containment issues continue to pressure both private and public managed […]January 1, 2006